Goldman Sachs’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-160,000
| Closed | -$1.85M | – | 6668 |
|
|
2021
Q4 | $1.85M | Buy |
+160,000
| New | +$1.78M | ﹤0.01% | 4317 |
|
|
2021
Q2 | – | Sell |
-370,000
| Closed | -$3.66M | – | 6305 |
|
|
2021
Q1 | $3.66M | Buy |
370,000
+297,700
| +412% | +$4.61M | ﹤0.01% | 3431 |
|
|
2020
Q4 | $1.67M | Buy |
+72,300
| New | +$1.48M | ﹤0.01% | 3852 |
|
|
2018
Q1 | – | Sell |
-300,000
| Closed | -$4.32M | – | 6052 |
|
|
2017
Q4 | $4.32M | Buy |
300,000
+400
| +0.1% | +$5.5K | ﹤0.01% | 3136 |
|
|
2017
Q3 | $4.52M | Buy |
299,600
+259,600
| +649% | +$3.43M | ﹤0.01% | 3249 |
|
|
2017
Q2 | $403K | Buy |
+40,000
| New | +$322K | ﹤0.01% | 5270 |
|
|
2016
Q3 | – | Sell |
-46,800
| Closed | -$256K | – | 7066 |
|
|
2016
Q2 | $256K | Sell |
46,800
-23,600
| -34% | -$165K | ﹤0.01% | 5479 |
|
|
2016
Q1 | $595K | Buy |
70,400
+39,600
| +129% | +$280K | ﹤0.01% | 4578 |
|
|
2015
Q4 | $299K | Buy |
+30,800
| New | +$278K | ﹤0.01% | 5353 |
|
|
2015
Q2 | – | Sell |
-23,600
| Closed | -$257K | – | 7312 |
|
|
2015
Q1 | $257K | Buy |
+23,600
| New | +$208K | ﹤0.01% | 5787 |
|
|
2013
Q4 | – | Sell |
-29,500
| Closed | -$68K | – | 6693 |
|
|
2013
Q3 | $68K | Hold |
29,500
| – | – | ﹤0.01% | 6253 |
|
|
2013
Q2 | $69K | Buy |
+29,500
| New | +$90.7K | ﹤0.01% | 5979 |
|
Other funds holding FOLD
Goldman Sachs's FOLD Position: Q2 2026 in Review
Goldman Sachs sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 11,556,008 shares — an estimated $167M sold.
Goldman Sachs first reported a position in FOLD in Q2 2013 and held it in 52 quarters. The position peaked at $167M in Q1 2026. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.
- Goldman Sachs reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
- Goldman Sachs sold 11,556,008 Amicus Therapeutics shares in Q2 2026, an estimated $167M.
- Goldman Sachs first reported a position in Amicus Therapeutics in Q2 2013 and held it in 52 quarters.
- Goldman Sachs's Amicus Therapeutics position peaked at $167M in Q1 2026.
- 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.